Nicholas Investment Partners LP Sells 473 Shares of C.R. Bard, Inc. (BCR)
Nicholas Investment Partners LP lowered its stake in C.R. Bard, Inc. (NYSE:BCR) by 4.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,882 shares of the company’s stock after selling 473 shares during the period. Nicholas Investment Partners LP’s holdings in C.R. Bard were worth $2,444,000 at the end of the most recent quarter.
A number of other large investors have also bought and sold shares of BCR. Advisory Services Network LLC increased its position in shares of C.R. Bard by 4.9% in the third quarter. Advisory Services Network LLC now owns 513 shares of the company’s stock worth $115,000 after buying an additional 24 shares during the period. Mycio Wealth Partners LLC increased its position in shares of C.R. Bard by 36.4% in the second quarter. Mycio Wealth Partners LLC now owns 599 shares of the company’s stock worth $141,000 after buying an additional 160 shares during the period. Penserra Capital Management LLC increased its position in shares of C.R. Bard by 100.0% in the third quarter. Penserra Capital Management LLC now owns 648 shares of the company’s stock worth $145,000 after buying an additional 324 shares during the period. Shinko Asset Management Co. Ltd. increased its position in shares of C.R. Bard by 60.1% in the third quarter. Shinko Asset Management Co. Ltd. now owns 975 shares of the company’s stock worth $219,000 after buying an additional 366 shares during the period. Finally, Private Advisor Group LLC purchased a new position in shares of C.R. Bard during the fourth quarter worth about $232,000. Institutional investors and hedge funds own 86.89% of the company’s stock.
C.R. Bard, Inc. (NYSE:BCR) traded up 0.15% during mid-day trading on Friday, hitting $242.15. 104,108 shares of the stock traded hands. The firm has a market capitalization of $17.44 billion, a P/E ratio of 34.45 and a beta of 0.63. C.R. Bard, Inc. has a 1-year low of $185.72 and a 1-year high of $242.68. The company has a 50-day moving average of $234.21 and a 200 day moving average of $222.72.
C.R. Bard (NYSE:BCR) last posted its quarterly earnings results on Thursday, January 26th. The company reported $2.77 EPS for the quarter, topping the Zacks’ consensus estimate of $2.74 by $0.03. C.R. Bard had a return on equity of 48.48% and a net margin of 14.31%. The company had revenue of $967.10 million for the quarter, compared to analysts’ expectations of $956.12 million. During the same period in the previous year, the firm earned $2.43 EPS. The firm’s revenue was up 10.0% compared to the same quarter last year. On average, equities research analysts anticipate that C.R. Bard, Inc. will post $11.64 EPS for the current year.
The firm also recently declared a quarterly dividend, which was paid on Friday, February 3rd. Investors of record on Monday, January 23rd were issued a $0.26 dividend. The ex-dividend date of this dividend was Thursday, January 19th. This represents a $1.04 dividend on an annualized basis and a yield of 0.43%. C.R. Bard’s dividend payout ratio is presently 14.77%.
This piece of content was first published by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international copyright laws. The correct version of this piece of content can be viewed at http://www.watchlistnews.com/nicholas-investment-partners-lp-sells-473-shares-of-c-r-bard-inc-bcr/1122453.html.
BCR has been the topic of a number of recent analyst reports. BMO Capital Markets upgraded shares of C.R. Bard from a “market perform” rating to an “outperform” rating and set a $240.00 price target on the stock in a research report on Wednesday, October 26th. They noted that the move was a valuation call. Zacks Investment Research upgraded shares of C.R. Bard from a “hold” rating to a “buy” rating and set a $241.00 price target on the stock in a research report on Thursday, October 27th. Morgan Stanley upgraded shares of C.R. Bard from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $240.00 to $260.00 in a research report on Tuesday, January 3rd. Raymond James Financial, Inc. upgraded shares of C.R. Bard from an “outperform” rating to a “strong-buy” rating and boosted their price target for the stock from $250.00 to $265.00 in a research report on Thursday, January 5th. Finally, JMP Securities boosted their price target on shares of C.R. Bard from $240.00 to $255.00 in a research report on Friday, January 27th. Eight equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. C.R. Bard has an average rating of “Buy” and an average target price of $244.14.
In related news, VP Betty D. Larson sold 3,292 shares of the business’s stock in a transaction that occurred on Friday, February 10th. The stock was sold at an average price of $240.92, for a total value of $793,108.64. Following the transaction, the vice president now directly owns 8,399 shares of the company’s stock, valued at approximately $2,023,487.08. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Vice Chairman John H. Weiland sold 14,091 shares of the business’s stock in a transaction that occurred on Tuesday, February 14th. The stock was sold at an average price of $240.49, for a total value of $3,388,744.59. Following the completion of the transaction, the insider now directly owns 68,978 shares in the company, valued at $16,588,519.22. The disclosure for this sale can be found here. Over the last three months, insiders sold 130,608 shares of company stock worth $30,537,656. 0.97% of the stock is owned by insiders.
C.R. Bard Company Profile
C. R. Bard, Inc (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities.
Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.